AxoGen, Inc.
AXGN
Positions held
Your positionsAXGN isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- AxoGen operates in the growing medical devices sector, focusing on nerve repair solutions, which is a niche with increasing demand due to rising awareness of nerve injuries.
- Revenue increased by 13% compared to the prior quarter, reaching $70 million.
- Gross margin remains strong at 72.7%, although it decreased slightly from the previous quarter.
- The company's financials show a concerning trend with a negative profit margin of -13.36%, indicating ongoing challenges in profitability.
- AxoGen's operating margin has worsened, now at -3.1%, reflecting operational inefficiencies.
- The overall score indicates a 'Strong Sell' signal with a score of -16.00, highlighting significant bearish market sentiment.
Fundamentals
| Market cap | $2.12B | Enterprise value | $1.85B | Trailing P/E | — | Forward P/E | 52.59 |
| PEG | 99.04 | Price / book | 7.58 | Beta | 1.17 | Dividend yield | 0.00% |
| Revenue growth | 23.1% | Earnings growth | — | Gross margin | 74.6% | Operating margin | -3.1% |
| Profit margin | -13.4% | ROE | -18.2% | ROA | -3.1% | Debt / equity | 0.08 |
| Current ratio | 6.60 | Free cash flow | $18.23M | Analyst recommendation | strong_buy | Mean target | $53.82 |
| 52w high | $52.91 | 52w low | $15.27 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $69.7M | $61.5M | $59.9M | $60.1M | $56.7M | — |
| Op margin | -3.1% | -4.6% | -16.3% | 3.2% | 3.0% | — |
| Net income | -$1.5M | -$19.6M | -$13.2M | $0.7M | $0.6M | — |
| Gross margin | 72.7% | 75.2% | 74.1% | 76.6% | 74.2% | — |
| Gross profit | $50.7M | $46.2M | $44.4M | $46.0M | $42.0M | — |
| Operating income | -$2.2M | -$2.8M | -$9.8M | $1.9M | $1.7M | — |
- Revenue +13% vs prior quarter ($70M vs $61M).
- Gross margin 72.7% (was 75.2% prior quarter).
- Operating margin expanded to -3.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $225M | $187M | $159M | $139M |
| Op margin | -3.5% | -1.8% | -13.5% | -21.4% |
| Net income | -$15.7M | -$10.0M | -$21.7M | -$28.9M |
| Gross margin | 74.3% | 75.8% | 76.6% | 78.5% |
| Gross profit | $167M | $142M | $122M | $109M |
| Operating income | -$7.8M | -$3.3M | -$21.5M | -$29.7M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls
2026-10-07 · Barclays Initiates Coverage on Axogen With Overweight Rating, $55 Price Target
2026-10-07 · Barclays Initiates Axogen at Overweight With $55 Price Target
2026-10-05 · Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen (AXGN)
2026-10-03 · Nasdaq Hits Fresh Ground on Chip and Software Strength as Dow, Small Caps Lag for the Week
2026-10-01 · Truist Cuts Price Target on Axogen to $53 From $60, Keeps Buy Rating
2026-09-30 · 3 Emerging Biotech Stocks With Significant Upside Potential
2026-09-10 · Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair
2026-09-10 · 2 Medical-Device Stocks Lighting Up the Options Pits
2026-09-10 · Sector Update: Healthcare Stocks Mixed Pre-Bell Thursday
2026-09-10 · Axogen Prices $208.7 Million Public Offering
Price (daily)
Full chart · RSI · MACD · patterns